Detalhe da pesquisa
1.
Gene-environmental regulation of the postnatal post-mitotic neuronal maturation.
Trends Genet
; 2024 Apr 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38658255
2.
Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia.
Blood
; 135(7): 463-471, 2020 02 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-31841594
3.
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.
N Engl J Med
; 378(25): 2386-2398, 2018 Jun 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-29860938
4.
Outcome heterogeneity of TP53-mutated myeloid neoplasms and the role of allogeneic hematopoietic cell transplantation.
Haematologica
; 109(3): 948-952, 2024 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37731390
5.
Impaired B cell immunity in acute myeloid leukemia patients after chemotherapy.
J Transl Med
; 15(1): 155, 2017 07 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28693586
6.
Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide.
Blood
; 125(19): 3024-31, 2015 May 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-25814532
7.
Final phase I substudy results of ivosidenib in patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome.
Blood Adv
; 2024 04 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-38640348
8.
Venetoclax in combination with hypomethylating agent for the treatment of advanced myeloproliferative neoplasms and acute myeloid leukemia with extramedullary disease.
Leuk Lymphoma
; 64(4): 846-855, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36744656
9.
Allogeneic Blood or Marrow Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Acute Lymphoblastic Leukemia in Patients Age ≥55 Years.
Transplant Cell Ther
; 29(3): 182.e1-182.e8, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36587740
10.
Genomic landscape of myelodysplastic/myeloproliferative neoplasm can predict response to hypomethylating agent therapy.
Leuk Lymphoma
; 63(8): 1942-1948, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35379077
11.
Nonmyeloablative Allogeneic Transplantation With Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia With IDH Mutations: A Single Center Experience.
Clin Lymphoma Myeloma Leuk
; 22(4): 260-269, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34750086
12.
Post-Transplantation Cyclophosphamide-Based Graft- versus-Host Disease Prophylaxis with Nonmyeloablative Conditioning for Blood or Marrow Transplantation for Myelofibrosis.
Transplant Cell Ther
; 28(5): 259.e1-259.e11, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35158092
13.
A phase II study of azacitidine in combination with granulocyte-macrophage colony-stimulating factor as maintenance treatment, after allogeneic blood or marrow transplantation in patients with poor-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Leuk Lymphoma
; 62(13): 3181-3191, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34284701
14.
Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia.
Blood Cancer Discov
; 2(6): 616-629, 2021 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-34778801
15.
Immunomodulation with pomalidomide at early lymphocyte recovery after induction chemotherapy in newly diagnosed AML and high-risk MDS.
Leukemia
; 34(6): 1563-1576, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31900407
16.
Allogeneic transplantation for Ph+ acute lymphoblastic leukemia with posttransplantation cyclophosphamide.
Blood Adv
; 4(20): 5078-5088, 2020 10 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-33080006
17.
Pilot trial of K562/GM-CSF whole-cell vaccination in MDS patients.
Leuk Lymphoma
; 59(12): 2801-2811, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29616857
18.
Timed sequential therapy for acute myelogenous leukemia: Results of a retrospective study of 301 patients and review of the literature.
Leuk Res
; 61: 25-32, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28869816
19.
Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults.
J Clin Oncol
; 33(28): 3152-61, 2015 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26261255
20.
Fibrinogen consumption and use of heparin are risk factors for delayed bleeding during acute promyelocytic leukemia induction.
Leuk Res
; 83: 106174, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31255938